 "Lupin to use MonoSol technology for developing paediatric products")
Lupin Ltd will use the US-based MonoSol Rx’s proprietary PharmFilm drug delivery technology to develop multiple paediatric products. A licensing agreement to this effect was signed by Lupin Pharmaceutical Inc, the US subsidiary of pharma major Lupin Limited, and MonoSol Rx yesterday.
MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. The US firm is a global leader in film-based drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development.
For patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, PharmFilm technology provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health. The technology can offer potential to support paediatric patients in particular, many of whom have difficulty with the currently available oral or injectable dosing of needed medications.
The agreement with MonoSol in line with Lupin’s focus on expanding into the specialty pharmaceutical market, and specifically, paediatric needs such as attention-deficit/hyperactivity disorder (ADHD).
“At Lupin, we are motivated by addressing urgent, unmet medical needs – and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission. Our alliance with MonoSol Rx will enable us to expand our family of paediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products,” said Paul McGarty, president, Lupin Pharmaceuticals.
Keith Kendall, CEO, MonoSol Rx, added, “We believe PharmFilm technology holds great promise for paediatric applications - enabling increased compliance and adherence in a difficult to treat population. By partnering with Lupin, whose commitment to support and expand within the paediatric and family-focused market matches our own commitment to helping paediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products.”
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%